Amphastar Pharmaceuticals (AMPH) Income from Continuing Operations (2013 - 2026)

Amphastar Pharmaceuticals' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 6420000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 74.61% year-over-year to 6420000.0; the TTM figure through Mar 2026 stood at 49723000.0 (down 133.82% YoY), while the FY2025 annual figure was 30858000.0, down 118.64% from the prior year.
• Income from Continuing Operations was 6420000.0 for Q1 2026 at Amphastar Pharmaceuticals, up from 104523000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 49612000.0 in Q3 2023 to a low of 104523000.0 in Q4 2025.
• Historically, Income from Continuing Operations has averaged 21950411.76 across 5 years, with a median of 26817000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations soared 530.36% in 2022, then plunged 340.96% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 33970000.0 in 2022, then gained by 7.95% to 36672000.0 in 2023, then gained by 18.29% to 43378000.0 in 2024, then slumped by 340.96% to 104523000.0 in 2025, then jumped by 106.14% to 6420000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 6420000.0 (Q1 2026), 104523000.0 (Q4 2025), and 17350000.0 (Q3 2025), per Business Quant data.